IRMD Iradimed Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IRMD

Price (delayed)

$93.43

Market cap

$1.19B

P/E Ratio

50.23

Dividend/share

$1.24

EPS

$1.86

Enterprise value

$1.14B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 96

IRADIMED CORPORATION is a leader in the development of innovative magnetic resonance imaging ('MRI') compatible medical devices. It's the only known provider of a non-magnetic intravenous ('IV') infusion pump system ...

Highlights
The company's debt has shrunk by 100% YoY
Iradimed's net income has increased by 19% YoY and by 5% from the previous quarter
Iradimed's quick ratio has decreased by 23% YoY and by 10% from the previous quarter
IRMD's price to earnings (P/E) is 15% higher than its 5-year quarterly average of 42.5 and 5% higher than its last 4 quarters average of 46.5
Sector: Healthcare
Industry: Medical Devices
Website: http://www.iradimed.com
Peers: COO DXCM EW

Key stats

What are the main financial stats of IRMD

IRMD stock price

How has the Iradimed stock price performed over time
Intraday
2.54%
1 week
1.35%
1 month
10.02%
1 year
53.72%
YTD
-3.96%
QTD
-2.94%

Financial performance

How have Iradimed's revenue and profit performed over time
Revenue
$86.28M
Gross profit
$66.3M
Operating income
$27.95M
Net income
$23.61M
Gross margin
76.8%
Net margin
27.4%
The company's operating income rose by 23% YoY and by 7% QoQ
Iradimed's net income has increased by 19% YoY and by 5% from the previous quarter
The gross profit is up by 15% YoY and by 3.1% QoQ
The company's revenue rose by 15% YoY and by 2.9% QoQ

Price vs fundamentals

How does IRMD's price correlate with its fundamentals

Growth

What is Iradimed's growth rate over time

Valuation

What is Iradimed stock price valuation
IRMD P/E details
P/E
50.23
P/B
12.12
P/S
13.84
EV/EBIT
37.7
EV/EBITDA
36
EV/Sales
13.19
Iradimed's EPS has increased by 18% YoY and by 5% QoQ
IRMD's price to earnings (P/E) is 15% higher than its 5-year quarterly average of 42.5 and 5% higher than its last 4 quarters average of 46.5
The price to book (P/B) is 50% higher than the 5-year quarterly average of 7.9 and 10% higher than the last 4 quarters average of 10.7
Iradimed's equity has increased by 9% YoY and by 4.1% QoQ
The price to sales (P/S) is 35% higher than the 5-year quarterly average of 10.0 and 8% higher than the last 4 quarters average of 12.5
The company's revenue rose by 15% YoY and by 2.9% QoQ

Efficiency

How efficient is Iradimed business performance
Iradimed's return on invested capital has increased by 4.6% QoQ but it has decreased by 2.2% YoY
Iradimed's return on equity has increased by 5% YoY and by 2.9% QoQ
Iradimed's return on sales has increased by 5% YoY and by 3.6% QoQ
The company's return on assets rose by 3.4% YoY and by 2.4% QoQ

Dividends

What is IRMD's dividend history
Dividend details
DPS
$1.24
Dividend yield
1.33%
Payout ratio
66.7%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Iradimed financials performed over time
Iradimed's total liabilities has increased by 36% YoY and by 12% QoQ
Iradimed's quick ratio has decreased by 23% YoY and by 10% from the previous quarter
The company's debt is 100% lower than its equity
The company's debt has shrunk by 100% YoY
Iradimed's equity has increased by 9% YoY and by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.